Online Matchmaking: EP PerMed Twinning Call 2026

25 Sept 2025 – 26 Feb 2026

Register
Register
Register

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.

Research organisation

www.irst.emr.it/itMeldola, Italy

About

The IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST) is a leading non-profit institution entirely dedicated to cancer research, treatment, and education. Located in northeastern Italy (Meldola-FC), IRST serves a population of over 1.1 million people and operates within the National Health Service through a robust public-private partnership. Recognized by the Italian Ministry of Health as a Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) since 2012, IRST plays a key role in advancing cancer care and research across the Emilia-Romagna region.

The institute’s mission is to close the gap between research and clinical practice by translating scientific discoveries into effective, personalized cancer treatments. IRST integrates advanced infrastructure, emerging technologies, and multidisciplinary expertise to deliver targeted, patient-specific interventions. Its model is based on a continuous, bidirectional exchange between clinical and biological research, ensuring that laboratory innovations are rapidly transferred to therapeutic strategies and that clinical needs drive scientific investigation.

Research at IRST spans a broad range of areas, including onco-hematological diseases, epidemiology and public health, immunotherapy and molecular oncology, radiometabolic and radiotherapy treatments, nuclear medicine, and imaging. Particular emphasis is placed on precision oncology, artificial intelligence, and data-driven medicine.

As part of the Emilia-Romagna Regional Health Service, IRST promotes and coordinates oncological research and clinical trials, provides infrastructure to support innovative treatments, and delivers highly specialized oncology services across the AUSL Romagna network.

Firmly embedded in the European research and innovation landscape, IRST actively contributes to international initiatives on innovative therapies, translational oncology, digital health, and personalized medicine, helping shape the future of cancer care beyond national borders.

Additional questions

Twinning role

Receiver institution – we have a concrete need and are looking to adopt or adapt a personalised medicine approach.Donor institution – we have a successful personalised medicine approach ready to share and support implementation elsewhere.

Representatives

Research and Innovation Manager

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.